Nilotinib Cf

Nilotinib, the active ingredient in Nilotinib Cf, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in adult patients and belongs to the antineoplastic therapeutic class, targeting cellular pathways that drive leukemic cell proliferation.

GNH USA supplies Nilotinib Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to strict quality standards and provides reliable logistics for global distribution.

Nilotinib is indicated for the treatment of chronic myeloid leukemia, a BCR‑ABL‑positive hematologic malignancy. It works within the tyrosine‑kinase‑inhibitor pathway to control disease progression.

- Chronic phase CML: achieves hematologic and cytogenetic remission. - Accelerated phase CML: reduces disease burden and delays progression. - Philadelphia chromosome‑positive CML: targets BCR‑ABL fusion protein to inhibit leukemic cell growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Rash: skin erythema or pruritus. - Headache: transient cranial discomfort. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: risk of cardiac arrhythmia. - Pancreatitis: inflammation of the pancreas. - Severe hepatic injury: marked elevation of liver enzymes. - Neutropenia: dangerously low white‑blood‑cell count. - Thrombocytopenia: reduced platelet levels. - Cardiac events: myocardial infarction or heart failure.

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications.

- Cardiac monitoring: evaluate QT interval and correct electrolyte abnormalities. - Hepatic function: check liver enzymes regularly. - Hematologic surveillance: monitor complete blood count for neutropenia or thrombocytopenia. - Drug interactions: avoid strong CYP3A4 inhibitors and concomitant QT‑prolonging agents. - Pregnancy and lactation: risk unknown; use only if benefits outweigh risks. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nilotinib may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): heighten risk of cardiac arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - Warfarin: potential alteration of anticoagulant effect. - Statins (e.g., simvastatin): increased risk of myopathy. - Digoxin: possible increase in serum concentration. - Proton pump inhibitors: may affect gastric pH and drug absorption.